Hepatology & Hepatitis CME

Target Audience: Physicians focusing on Infectious Diseases. 

In-depth CME Review of Gastrointestinal Diseases

Gastroenterology and Hepatology Board Review is an online video CME program covering normal function, signs, symptoms, and diseases of the gastrointestinal organs — from the esophagus and stomach to the small intestine, colon, liver, pancreas, and biliary tract.

This continuing medical education program includes 40+ one-hour lectures delivered by recognized experts with extensive clinical experience. You’ll benefit from the decision-making expertise of these skilled educators as they discuss diagnostic procedures, medical therapy, surgical therapy, and procedural therapy. Presentations combine scientific evidence and clinical judgment, culminating with recommendations for the most appropriate care and improved patient outcomes.

The management of critically ill patients with liver disease requires the expertise of a variety of healthcare providers from multiple disciplines. Cleveland Clinic addresses their multifaceted educational needs with the Interprofessional Approach to Liver Disease. Physicians, nurses and physician assistants will benefit from the latest strategies and evidence based management guidance from an expert faculty. Worth 14 AMA PRA Category I Credits™, with ANCC and AAPA accreditation provided as well. This enduring material also qualifies for 14 ABIM MOC points, with NO POST TEST.

Earn CME Credits and Board Review Prep

The Brigham Board Review in Gastroenterology and Hepatology provides in-depth CME coverage of wide-ranging topics, keeping you abreast of the latest advances in the field.

This board review course includes case-based lectures on topics like GERD, gastrointestinal bleeding, gastric and small bowel motility disorders, acute liver failure, celiac disease, benign and malignant biliary diseases, and more. It’s online CME that will help you to better:

• Apply latest/recommended gastroenterology guidelines in clinical practice
• Attain the latest knowledge on clinical presentation, pathologic features, diagnosis, and differential diagnosis of various gastroenterology disorders
• Stay updated on an expanding array of therapeutic options for diverse gastrohepatic disorders
• Evaluate and interpret up-to-date literature for evidence-based clinical practice in gastroenterology
• Prepare for ABIM certification/recertification gastroenterology examinations

Learning Objectives

At the conclusion of this activity, the participant will be able to:

• Apply current/recommended gastroenterology guidelines in clinical practice
• Perform differential diagnosis of complex clinical presentations related to gastroenterology disorders
• Identify and apply current therapeutic options for specific gastroenterology disorders
• Analyze and interpret up-to-date literature relevant to clinical practice in gastroenterology
• Recognize and apply knowledge of pathophysiology as it applies to management of gastroenterology disorders
• Apply knowledge gained to the ABIM certification/recertification gastroenterology examinations

Intended Audience

This educational activity was designed for fellows/trainees and practicing gastroenterology specialists (MDs) and other professional affiliates (internists with an interest in gastroenterology) who are preparing to take ABIM Board Review or Recertification Examinations or who seek CME activities to improve patient care in the area of gastroenterology medicine. The target audience is regional, national and international.

Activity Description / Statement of Need:

In this online, self-learning activity:

Non-alcoholic steatohepatitis (NASH) is a form of non-alcoholic fatty liver disease (NAFLD) characterized by steatosis, with the accumulation of fat in the liver in excess of five percent of the liver’s weight, together with hepatic inflammation in the presence or absence of fibrosis. Risk factors for NASH include a number of comorbid metabolic diseases and disorders, including metabolic syndrome, obesity, type 2 diabetes, hypertension, and dyslipidemia. The prevalence of NASH is estimated to be 1.5%-6.45% of the U.S. population, and prevalence of NASH among NAFLD patients to be 59.1% globally.

Target Audience:

The following HCPs in: Gastroenterology, hepatology, and endocrinology; physician assistants, nurse practitioners, and pharmacists who practice in the aforementioned areas of specialty; and those who otherwise have an interest in or commonly care for or clinically encounter patients with NAFLD.